Therapeutic agents for metabolic diseases comprising delivery systems based on metal nanoparticle-nucleic acid conjugates
By covalently binding double-stranded DNA to gold nanoparticles, the safety and stability issues of DNA delivery were resolved, enabling independent expression within the cell nucleus for the treatment of metabolic diseases.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NES BIOTECHNOLOGY CO LTD
- Filing Date
- 2024-11-21
- Publication Date
- 2026-06-19
AI Technical Summary
Existing technologies cannot safely and effectively deliver double-stranded DNA into the cell nucleus, leading to side effects and gene integration risks in DNA vaccines. Furthermore, traditional vectors have biocompatibility and stability issues.
Using gold nanoparticles as a carrier, double-stranded DNA is directly bound to its surface via covalent bonds. Taking advantage of the high biocompatibility and stability of gold nanoparticles, DNA can be independently expressed in the cell nucleus, expressing insulin or substances that promote insulin secretion.
Stable delivery and independent expression of double-stranded DNA were achieved, reducing the risk of immune response and improving the efficacy of treatment for metabolic diseases.
Smart Images

Figure CN122249240A_ABST